rheumatoid arthritis

AbbVie Inc (NYSE: ABBV) announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for rheumatoid arthritis (RA).  The update follows a Drug Safety Communication (DSC) issued in September by the FDA following its final review of the...

The FDA extended the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) rheumatoid arthritis drug Olumiant (baricitinib) to be used as a sole treatment for hospitalized COVID-19 patients who need...

The FDA has granted Navidea Biopharmaceuticals Inc's (NYSE: NAVB) request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the Phase 3 trial.  The meeting will take place on September 1 via conference call....

The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial portfolio of preferred medications to treat COVID-19, reports Reuters. The selection of drugs is part of the E.U. Strategy...

Pfizer Inc (NYSE: PFE) said that its oral rheumatoid arthritis drug Xeljanz (tofacitinib) reduced death or respiratory failure in hospitalized COVID-19 patients with pneumonia in Brazil, meeting the study’s primary goal. Results of the study, which tested the drug in 289 hospitalized...

Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients. Discovered by Incyte Corporation...

AbbVie Inc (NYSE: ABBV) has announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with Rinvoq (upadacitinib) resulted in sustained improvements in psoriatic arthritis patients who did not respond to disease-modifying anti-...

Sorrento Therapeutics Inc (NASDAQ: SRNE) reported positive initial results from the Phase 1B study of its Sofusa Lymphatic Delivery System administering Amgen Inc’s (NASDAQ: AMGN) Enbrel for rheumatoid arthritis. Sofusa delivers biologic therapies through the...

Biogen Inc (NASDAQ: BIIB) and Bio-Thera Solutions Ltd have entered into a commercialization and license agreement to develop, manufacture, and commercialize BAT1806, a proposed biosimilar referencing Genentech's Actemra (tocilizumab). The anti-interleukin-6 (IL-6) receptor...

When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...